Available disease-modifying therapies (DMTs) for Gaucher disease can decrease the levels of lyso-Gb1, a biomarker of disease burden, but…
Articles by Steve Bryson PhD
Differences in nerve cell function may explain why some people with Gaucher disease develop the neurodegenerative Parkinson’s disease and others…
New Jersey’s newborn screening (NBS) program for Gaucher disease has proven itself effective at identifying many newborns with the…
Researchers identified six previously unknown mutations in the GBA1 gene linked to Gaucher disease, according to a case series…
Gaucher disease doesn’t seem to have a major impact on conception, pregnancy, and childbirth, according to a…
An investigational gene therapy aiming to restore GBA gene function — which is defective…
A substrate reduction therapy (SRT) candidate known as Genz-667161 effectively reduced the buildup of glucocerebroside in the…
People with type 1 Gaucher disease have higher blood levels of two pro-inflammatory proteins than do…
After two years of Cerdelga (eliglustat) therapy, patients with Gaucher…
Four distinct genetic profiles in Gaucher disease (GD) patients within a single family highlight the variability in disease…